Sol Gel Technologies opened lower at $62.03, compared with its previous close of $63.40. In the last trading session, the stock traded between $53.56 and $63.00. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Sol Gel Technologies is now worth
$ 61.86
Resulting in a loss of
$ 38.14 (38.14%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-7.23 (-11.40%)
Day High
$63.00
Day Low
$53.56
Day Open
$62.03
Prev Close
$63.40
Volume
43,382
1W Return
-16.93%
1M Return
-22.41%
3M Return
-27.80%
6M Return
-19.73%
1Y Return
76.18%
Fundamentals
Market Cap ($ Mn)
184
PE Ratio
-
PB Ratio
4.68
PEG Ratio
-
ROE
-23.61%
ROCE
-27.00%
EPS (TTM)
$-1.12
Investment Returns
1 Week
-16.93%
1 Month
-22.41%
3 Months
-27.80%
6 Months
-19.73%
9 Months
-15.02%
Financials
Quarterly
All values in $ Mn
1.0
Mar 25
17.3
Jun 25
0.4
Sep 25
0.7
Dec 25
0.1
Mar 26
0.6
Jun 26
Updates
12Nov
Sol-Gel Technologies Q3 Results: Loss narrows 19.25%, revenue falls 89.75%
Sol-Gel Technologies reported a loss of $(1.72) per share, beating the $(2.07) estimate by 16.91%. Quarterly revenue fell 89.75% YoY to $41.000 thousand, missing the $150.000 thousand consensus by 72.67%. Loss per share improved from $(2.13) in the same period last year. The earnings beat contrasts with a severe top-line contraction, indicating cost-driven rather than growth-driven results.
Today
19Oct
HC Wainwright maintains Buy rating on Sol-Gel Technologies at $110 target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Sol-Gel Technologies. The firm maintained its price target of $110 per share. The rating reaffirms the analyst's confidence in the company's valuation.
24 days ago
30Sep
Sol-Gel Technologies to host SGT-610 investor event on Oct 14
Sol-Gel Technologies schedules KOL investor event for SGT-610 on October 14, 2026. Event highlights lack of effective therapies for Gorlin Syndrome patients. Speakers include experts from Stanford Cancer Institute and Penn State College of Medicine. SGT-610 is a Phase 3 topical hedgehog inhibitor with breakthrough designation.
1mo ago
20Aug
Sol-Gel Technologies Q2 Results: EPS beats estimate, sales up 688%
Sol-Gel Technologies reported Q2 EPS of $(1.13), beating the $(2.31) estimate by 51.08%. Sales of $591,000 exceeded the $75,000 estimate by 688%, but fell 96.58% YoY from $17.261 million. EPS declined 127.1% YoY from $4.17.
2mo ago
20Jul
HC Wainwright reiterates Buy on Sol-Gel Technologies
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Sol-Gel Technologies, maintaining a price target of $110. The stock trades on NASDAQ under the ticker SLGL.
3mo ago
24Jun
Mizuho initiates coverage on Sol-Gel Technologies with Outperform rating
Mizuho analyst Uy Ear initiated coverage on Sol-Gel Technologies with an Outperform rating and a price target of $285. The stock trades on NASDAQ under the ticker SLGL.
